機械人TMS定位系統
Zeta Surgical 產品ZetaMove獲FDA批准
Zeta Surgical 推出 Zeta TMS Robotic System,一套機械人經顱磁刺激定位平台,設計旨在自動化線圈擺放,並於病人移動期間,維持精準定位。此獲 FDA 認證的 Class II 立體定向儀器,結合實時導航、機械人線圈定位及自動動作補償功能,支援更精準、更可重複的治療輸送。
此系統持續追蹤病人的動作,並調整 TMS 線圈,以保持刺激聚焦於目標腦部區域。Zeta 表示,此平台提供亞毫米級的定位精準度,並可於一分鐘以內完成設置。準確度及易用性測試,與哈佛醫學院及劍橋大學合作進行,惟此公布並未提供病人療效數據,或商業部署時間表。
對病人及臨床醫生而言,此系統有望減少人手重新調整線圈的次數,並支援更一致的 TMS 治療環節。此認證,反映出市場對能標準化非侵入性神經調節工作流程的機械人及導航技術,興趣日益增加。
英文原文
Zeta Surgical introduced the Zeta TMS Robotic System, a robotic transcranial magnetic stimulation positioning platform designed to automate coil placement and maintain targeting during patient movement. The FDA-cleared Class II stereotaxic instrument combines real-time navigation, robotic coil positioning and automatic motion compensation to support more precise and repeatable treatment delivery.
The system continuously tracks patient movement and adjusts the TMS coil to keep stimulation focused on the intended brain region. Zeta said the platform offers submillimeter-level positioning accuracy and can be set up in less than one minute. Accuracy and usability testing was conducted in collaboration with Harvard Medical School and the University of Cambridge, although the announcement did not provide patient outcome data or a commercial deployment timeline.
For patients and clinicians, the system could reduce manual coil readjustments and support more consistent TMS sessions. The clearance reflects growing interest in robotics and navigation technology that standardize noninvasive neuromodulation workflows.
- 來源
- Trend Hunter
- 發布
- 2026-07-31
- 品類
- Robots
- 出處
- mobihealthnews, zetasurgical